Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Soluble P-selectin glycoprotein ligand - a possible new target in ulcerative colitis (CROSBI ID 254115)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Ajduković, Jasna ; Salamunić, Ilza ; Hozo, Izet ; Despalatović, Bruna ; Šimunić, Miroslav ; Bonacin, Damir ; Puljiz, Željko ; Trgo, Gorana ; Šundov, Željko ; Tonkić, Ante Soluble P-selectin glycoprotein ligand - a possible new target in ulcerative colitis // Bratislavské lekárske listy, 116 (2015), 3; 147-149. doi: 10.4149/BLL_2015_029

Podaci o odgovornosti

Ajduković, Jasna ; Salamunić, Ilza ; Hozo, Izet ; Despalatović, Bruna ; Šimunić, Miroslav ; Bonacin, Damir ; Puljiz, Željko ; Trgo, Gorana ; Šundov, Željko ; Tonkić, Ante

engleski

Soluble P-selectin glycoprotein ligand - a possible new target in ulcerative colitis

Background: The main characteristic of active infl ammatory bowel disease (IBD) is the neutrophil infi ltration into the intestinal lamina propria, where neutrophils usually do not reside. Selectins are cell surface glycoproteins responsible for binding the leukocytes to vascular cells and their extravasation into the surrounding tissue. They show high affi nity to P-selectin glycoprotein ligand-1 (PSGL-1) receptors. PSGL-1 is expressed on the surface of all leukocytes and they mediate the rolling of neutrophils on P-selectin. Soluble PSGL-1 acts competitively with cellular PSGL in many physiological and pathological processes. The aim of our study was to compare serum sPSGL-1 concentration in the blood of patients with ulcerative colitis (UC) and healthy control subjects. Methods: Serum concentrations of sPSGL-1 were measured in 20 patients with UC and 20 control subjects. Two-layer immunoenzyme procedure (ELISA) was used. Results: The mean (± standard deviation) serum concentrations of sPSGL-1 in patients with UC and controls were 349.97±75.40 U/mL and 284.39±52.40 U/mL, respectively (p=0.003). Conclusion: In the present study, we showed that patients with UC had signifi cantly higher sPSGL-1 blood values in comparison with healthy subjects. A short-term blockade with anti- PSGL-1 antibodies could block the transport of neutrophils and decrease UC activity. Thus it could possibly be employed in a new therapeutic approach to the treatment of UC (Fig. 1, Ref. 25). Text in PDF www.elis.sk. Key words: ulcerative colitis, P-selectin glycoprotein ligand-1.

ulcerative colitis ; P-selectin glycoprotein ligand-1

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

116 (3)

2015.

147-149

objavljeno

0006-9248

1336-0345

10.4149/BLL_2015_029

Povezanost rada

Kliničke medicinske znanosti, Temeljne medicinske znanosti

Poveznice
Indeksiranost